Pauline Latzer

Aug 10, 2024 | nature.com | Pauline Latzer |Florian Battke |Till-Karsten Hauser |Christian la Fougère |Uwe M. Martens |Deborah Blumenthal | +8 more

AbstractCurrent treatment outcome of patients with glioblastoma (GBM) remains poor. Following standard therapy, recurrence is universal with limited survival. Tumors from 173 GBM patients are analysed for somatic mutations to generate a personalized peptide vaccine targeting tumor-specific neoantigens. All patients were treated within the scope of an individual healing attempt.